These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Fluid Biomarkers in Clinical Trials for Alzheimer's Disease: Current and Future Application. Yang J; Jia L; Li Y; Qiu Q; Quan M; Jia J J Alzheimers Dis; 2021; 81(1):19-32. PubMed ID: 33749646 [TBL] [Abstract][Full Text] [Related]
9. Clinical significance of fluid biomarkers in Alzheimer's Disease. Lewczuk P; Łukaszewicz-Zając M; Mroczko P; Kornhuber J Pharmacol Rep; 2020 Jun; 72(3):528-542. PubMed ID: 32385624 [TBL] [Abstract][Full Text] [Related]
10. Blood-based high sensitivity measurements of beta-amyloid and phosphorylated tau as biomarkers of Alzheimer's disease: a focused review on recent advances. Chong JR; Ashton NJ; Karikari TK; Tanaka T; Schöll M; Zetterberg H; Blennow K; Chen CP; Lai MKP J Neurol Neurosurg Psychiatry; 2021 Nov; 92(11):1231-1241. PubMed ID: 34510001 [TBL] [Abstract][Full Text] [Related]
11. Cerebrospinal fluid biomarkers for diagnosis of Alzheimer's disease: beta-amyloid(1-42), tau, phospho-tau-181 and total protein. Marksteiner J; Hinterhuber H; Humpel C Drugs Today (Barc); 2007 Jun; 43(6):423-31. PubMed ID: 17612711 [TBL] [Abstract][Full Text] [Related]
13. Diagnosis of Alzheimer's disease utilizing amyloid and tau as fluid biomarkers. Lee JC; Kim SJ; Hong S; Kim Y Exp Mol Med; 2019 May; 51(5):1-10. PubMed ID: 31073121 [TBL] [Abstract][Full Text] [Related]
14. Biomarkers for Alzheimer's disease: current status and prospects for the future. Blennow K; Zetterberg H J Intern Med; 2018 Dec; 284(6):643-663. PubMed ID: 30051512 [TBL] [Abstract][Full Text] [Related]